appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Wrobleski et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: